|
Biocommerce Data's Biotechnology Directory is a database concerned
with the business aspects of biotechnology and the commercial
applications of biological sciences worldwide. The company profile
records contain directory-style entries on organisations located
throughout the world. While the file contains two types of record
(company profile and abstract records), only the company profile
records are updated. Abstract records, while retained in CELL
are no longer updated. Abstacts of commercial biotechnology news
from trade journals, scientific periodicals, newsletters and
newspapers are available from Jan 1981 to Aug 2004 only.
CELL covers the biotechnologies of:
biological control, biomediation, biotransformation, cell culture,
cell hybridisation, DNA probes, fermentation, genetic engineering,
genomics, immunodiagnostics, industrial enzymes, monoclonal
antibodies, protein engneering, recombinant DNA, tissue culture, and
transgenic animals and plants;
and the commercial aspects of:
biochemistry, genetics, immunology, microbiology, molecular biology
and their applications in:
agriculture, animal production, brewing, chemical manufacture, crop
protection, diagnostic tests, energy production, food technology,
health care, horticulture, medicine, pesticides, veterinary
sciences, and waste treatment.
CELL corresponds in part to the printed publications: Abstracts
in BioCommerce (ABC) 1981-1996, BioCommerce Abstracts (BCA) 1997-
2004, The European Biotechnology Directory and the UK Biotechnology
Handbook.
Sources:
Directory entries are compiled from questionnaires, updated from
abstracted articles and verified regularly. Articles cited in
Biocommerce Abstracts and Directory are taken from over 100 English
language specialist and popular media sources, mainly published in
the USA and United Kingdom. Each abstract may cite several sources
where the articles contain substantially the same information and
typically, at least two sources are given.
Accession number & update
00165909 19980307.
Source
Financial-Times 20JAN1998, Vol(No)(33,502) page(s) 21;
Animal-Pharm 23JAN1998, Vol(No)(389) page(s) 6;
Agricultural-Supply-Industry 23JAN1998, Vol(No)28(4) page(s)
1; Irish-Independent 21JAN1998, page (s) 14; New-Scientist
31JAN1998, Vol(No)(2119) page(s) 5; Marketletter
26JAN1998, Vol(No)25(4) page(s) 4.
Publication year
1998.
Company name
Proteus International plc, UK (1032); Enfer Scientific Ltd,
Ireland (32727); SuperValu Supermarkets, Ireland (44864);
Department of Agriculture, Ireland, Ireland (36554);
Department of Agriculture, Northern Ireland, UK (15593).
Abstract
The Irish supermarket chain, SuperValu Supermarkets, has
started selling beef which has been tested by Enfer
Scientific to confirm that it is free of prions using
diagnostic test technology licensed from Proteus
International. The test was developed to detect bovine
spongiform encephalopathy (BSE). Proteus International's
share price increased by 23p to close at 83p following
news that the test was being commercially used.
Abstract type
1 Company information; Abstract.
Entry date
19980202.
Company profile:
Accession number & update
01000435 19980320.
Company name
Amgen Inc, USA (1134).
Address
Amgen Inc.
1 Amgen Center.
Thousand Oaks, CA 91320-1789.
USA.
Telecommunications
TELEPHONE: (805) 447-1000
TELEFAX: (805) 447-1010
URL: http://www.amgen.com
Organisation type
100 Company-main-site.
Employees
More than 1,000 staff.
Descriptors
Products and Services: Cytokines-lymphokines; Growth-factors;
Hormones; Therapeutic-biologicals
Interest Areas: Cell-tissue-culture; Endocrinology;
Fermentation; Genetic-engineering; Haematology; Human-
healthcare; Inflammation; Neurology; Oncology-cancer;
Pharmaceuticals; Fermentation; Genetic-engineering;
Pharmaceuticals.
Text
Amgen is a major biotechnology company that discovers,
develops, markets and manufactures human therapeutics
based on advances in cellular and molecular biology for
healthcare markets. Its common stock is traded on the
National Association of Securities Dealers Automated
Quotation (NASDAQ) system under the symbol AMGN. Amgen
produces recombinant human erythropoietin (EPO) called
EPOGEN (RTM) (Epoetin alpha) for stimulating the production
of red blood cells in patients undergoing dialysis and
NEUPOGEN (RTM) (Filgrastim) which is a recombinant human
granulocyte colony stimulating factor (G-CSF) for
use as an adjunct to chemotherapy for certain cancer patients.
NEUPOGEN is approved around the world for treating cancer
and in certain countries for use in reduction of the duration
of neutropenia following autologous and allogeneic bone
marrow transplantation and in the treatment of severe
chronic neutropenia. Amgen has also developed INFERGEN (RTM)
(interferon alfacon-1) for treating patients with hepatitis
C virus (HCV) and STEMGEN. Amgen has many other product
candidates undergoing clinical trial investigations including
novel erthyropoiesis stimulating protein (NESP) for treating
anaemia associated with chronic renal failure, R-568 for
treating secondary hyperparathyroidism, leptin for treating
obesity, tumour necrosis factor (TNF-bp) and interleukin-1
receptor antagonist (IL-1ra) for treating rheumatoid
arthritis (RA), glial derived neurotrophic factor
(GDNF) for treating Parkinson's disease and polyethylene
glycol megakaryocyte growth and development factor (PEG-
MGDF) for treating thrombocytopenia induced by high dose
chemotherapy. Amgen acquired Synergen on 31 December 1994.
Management
Mr David Kaye, Associate Director, Corporate Communications;
Ms Kate Falberg, VP, Chief Accounting Officer and
Corporate Controller;
Mr Gordon M Binder, Chairman and Chief Executive Officer
(CEO);
Dr N Kirby Alton, Senior Vice President, Development;
Dr Stanley Benson, Senior Vice President, Sales and Marketing;
Mr Lawrence M Souza, Senior Vice President, Research;
Mr Daryl D Hill, Senior Vice President Quality and Compliance;
Mr William L Ashton, Vice President, US Sales;
Mr Edward F Garnett, Vice President, Human Resources;
Mr Steven M Odre, Vice President, Intellectual Prop & Assoc
General Counsel;
Ms Sarah H Crampton, Director, Investor Relations;
Dr Bruce Wallace, Corporate Manager of Environmental
Health and Safety;
Mr George Vanderne, Vice President, Secretary and General
Counsel;
Dr George Morstyn, Vice President, Chief Medical Officer and
Clinical Develop;
Ms Kathleen M Wiltsey, Vice President, Product Licensing;
Mr Kevin W Sharer, Chief Operating Officer (COO) and
President;
Mr Peter B Teeley, Vice President, Government and Public
Relations;
Dr Linda R Wudl, Vice President, Quality Assurance and
Quality Control;
Dr Alan Herman, Laboratory Head, Analytical Research and
Development;
Mr Michael P Bevilacqua, Vice President, Inflammation and
Medicinal Chemistry;
Mr Thomas R Ulich, Vice President, Preclinical Development;
Dr Colin Pitt, Director, Pharmaceutics and Drug Delivery;
Mr Robert S Attiyeh, Senior Vice President, Finance and
Corp Devel and CFO;
Mr James Grant, Associate Manager for Research Affairs;
Mr Larry May, Treasurer;
Mr Dennis Fenton, Senior Vice President, Operations;
Dr Franklin D Collins, Vice President of Neuroscience;
Mr Chris Giffin, Manager, Product Licensing;
Mr Craig L Brooks, Vice President, Product Marketing;
Mr George A Vandeman, Senior Vice President, General
Counsel and Secretary;
Mr Aart Brouwer, Vice President, Europe;
Ms Martha E Vincent-Gattis, Vice President, Clinical Research;
Ms Rita Vorten, Director of Government Relations;
Mr Edward E Bjurstrom, Vice President, Manufacturing.
Abstract type
Profile.
Financial information
Year founded: 1980
Financial year: 1997
Financial year end date: 31/12/1997
Revenues in this financial year: $2.4 billion
Profit (or Loss) in this financial year: $645M
Research expenditure in this financial year: $600M
Employees at main site on 31/12/1997: 5200.
Entry date
19980213.
Label/description Example
AN Accession number 1_: 00165909
& update 2_: 19980307.AN.
SO Source 3_: FINANCIAL-TIMES.SO.
YR Publication year 4_: YR=1998
CO Company name 5_: AMGEN.CO.
or 6_: 1134.CO.
To retrieve company profiles
only, use .CX. : 7_: AMGEN.CX.
AD Address 8_: THOUSAND ADJ OAKS.AD.
If required, use also these
specific paragraphs:
ST - Street 9_: AMGEN ADJ CENTER.ST.
LO - Location 10_: THOUSAND ADJ OAKS.LO.
CN - Country 11_: USA.CN.
TL Telecommunications - Display only -
NT Notes
May include former company
names 12_: ORACLE.NT.
DE Descriptors
(company profiles only) 13_: GENETIC-ENGINEERING.DE.
or 14_: GENETIC ADJ
ENGINEERING.DE.
TX Text (company profiles) 15_: EPO WITH DIALYSIS.TX..
AB Abstract (bibliographic
records) 16_: BSE WITH TEST.AB.
MM Management 17_: DAVID WITH KAYE.MM..
AT Abstract type 18_: AT=PAT.
AT=P - company profiles
AT=A - bibliographic records
FI Financial information
May include: year founded,
financial year end date,
revenues, profit/loss, research
expenditure, staff numbers 19_: RESEARCH WITH
EXPENDITURE.FI.
ED Entry date (date added to
datbase producer's system) 20_: 19880212.ED.
1_: BSE$1
UDATE Update date YYYYMMDD 2_: ..L 1 UDATE>19980201
UMONTH Update month YYYYMM 3_: ..L 1 UMONTH=1998903
YEAR Publication year YYYY 4_: ..L 1 YEAR>1996
ED Entry date YYYYMMDD 5_: ..L 1 ED>19970630.
By paragraph: company name,
abstract, text _: ..P 1 CO, AB, TX 1-10
SHORT AN SO YR CO AD TL NT AB AT
MEDIUM AN SO YR CO AD TL NT DE AB TX AT
LONG AN SO YR CO AD TL NT DE AB TX MM AT FI
FREE AN YR AT ED
ALL AN SO YR CO AD CX ST LO CN TL NT HI EM DE AB TX MM AT ED
_: ..P 1 LONG 1,3,5-7.
BIOCOMMERCE ABSTRACTS & DIRECTORY (CELL):
This Database is copyrighted by BioCommerce Data Ltd and may not be
duplicated or stored in hardcopy or machine-readable form without
written authorisation from the producers, except that up to 5%
of the abstracts and 5% of the directory records may be stored
temporarily (for up to 7 days) in electronic form to enable
reformatting or editing for internal use.
The reproduction of up to 5 copies of any search output is
permitted for use within a customer's organisation.
The generation of mailing labels or any kind of mailing
list from the directory records in the Database is not permitted.
Resale or free distribution of any data to third parties
is expressly prohibited. BioCommerce Data takes care to abstract
articles accurately but does not accept liability for any errors or
omissions, cannot be held responsible for bias or mistakes in source
material, makes no warranties, express or implied of merchantability
or fitness for a particular purpose of and assumes no responsibility
for customers' use of the data. Use of the Database will imply
acceptance of these terms.
Back to the Datasheet Index Page
© 2008 Dialog DataStar
|